About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
For information about YCANTH™ or to request a representative, visit YCANTHPro.com
Press Releases
Press Releases
Year
2018
2019
2020
2021
2022
2023
2024
Submit
December 20, 2024
Verrica Provides Business and Operational Update
December 9, 2024
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 6, 2024
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
November 21, 2024
Verrica Announces Pricing of $42.0 Million Public Offering
November 20, 2024
Verrica Announces Proposed Public Offering
1
2
3
4
5
6
next >
